This MedLibrary.org supplementary page on Everolimus is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Everolimus
|
|
| Systematic (IUPAC) name | |
| dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone | |
| Identifiers | |
| CAS number | |
| ATC code | L04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C53H83NO14 |
| Mol. mass | 958.224 g/mol |
| Synonyms | 42-O-(2-hydroxyethyl)rapamycin |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Everolimus (RAD-001) (marketed as Certican by Novartis) is a derivative of Rapamycin (sirolimus) (the structure can be written as 42-O-(2-hydroxyethyl)rapamycin), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. Much research has also been conducted on Everolimus and other mTOR inhibitors for use in a number of cancers.
Although it does not have FDA approval in the USA, it is approved for use in Europe and Australia, and Phase III trials are being conducted in the US.
Contents |
Mechanism
In a similar fashion to other mTOR inhibitors its effect is solely on the mTORC1 protein and not on the mTORC2 protein. This can lead to a hyper-activation of the kinase AKT via inhibition on the mTORC1 negative feedback loop while not inhibiting the mTORC2 positive feedback to AKT. This AKT elevation can lead to longer survival in some cell types.
Role in heart transplantation
Everolimus may have a role in heart transplantation as it has been shown to reduce chronic allograft vasculopathy in such transplants. It also may have a similar role to sirolimus in kidney and other transplants.1
Contraindications
The contra-indication in the use of everolimus is a certain rise in cholesterol levels and therefore an increased cardio-vascular risk.
Use in vascular stents
Everolimus is used in drug-eluting coronary stents as an immunosuppressant to prevent restenosis. Abbott Vascular produces an everolimus-eluting stent called the Xience V, which is approved for sale and available in Europe. It utilizes the Multi-Link Vision cobalt chromium stent platform and Novartis' everolimus. The product is also currently an investigational device in the United States and Japan. It is also available under a private-label version called the PROMUS Everolimus-Eluting Coronary Stent System and it is currently available in most major European and Asia-Pacific markets.
References
- ^ Eisen HJ, Tuzcu EM, Dorent R, et al: Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. New England Journal of Medicine 2003; 349:847-858
Chemical modification of rapamycin: the discovery of SDZ RAD. PMID: 9723437
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 23 December 2008, at 07:41.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Everolimus".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.